

## Monoclonal Antibodies: Xolair – NASAL POLYPS

### Member Information

1. Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_  
3. Trillium ID #: \_\_\_\_\_ 4. Date of Birth: \_\_\_\_\_ 5. Gender: \_\_\_\_\_

### Prescriber Information

1. Prescriber Name: \_\_\_\_\_ 2. NPI #: \_\_\_\_\_  
3. Requestor Name (Nurse/Office Staff): \_\_\_\_\_  
4. Mailing Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
5. Phone #: \_\_\_\_\_ Ext. \_\_\_\_\_ Fax #: \_\_\_\_\_

### Drug Information

1. Drug Name: **Xolair** 2. Strength: \_\_\_\_\_ 3. Quantity per 30 Days: \_\_\_\_\_  
4. Length of Therapy (in Days): ☐ up to 30 Days ☐ 60 Days ☐ 90 Days ☐ 120 Days ☐ 180 Days ☐ 365 Days

### Clinical Information

#### Nasal Polyps: New Therapy

1. Is the member 18 years of age or older? ☐ **Yes** ☐ **No**  
2. Does the member weigh between 30kg (66lbs) and 150kg (330lbs)? ☐ **Yes** ☐ **No**  
**Member's Weight:** \_\_\_\_\_  
3. Does the member have an IgE level above 30IU/ml? ☐ **Yes** ☐ **No**  
**Please list level:** \_\_\_\_\_  
4. Does the member have a diagnosis of Nasal Polyps? ☐ **Yes** ☐ **No**  
5. Has the member tried and failed monotherapy with nasal steroids? ☐ **Yes** ☐ **No**  
6. Will the member continue to receive intranasal steroid concomitantly? ☐ **Yes** ☐ **No**

#### Nasal Polyps- Continuation of Therapy (please answer questions 1-7)

7. Is the member receiving continued clinical benefit from baseline supported by medical records? ☐ **Yes** ☐ **No**  
*\*If yes, please attach medical records\**

Signature of Prescriber: \_\_\_\_\_ Date: \_\_\_\_\_

**(Prescriber Signature Mandatory)**

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.